This is exciting. Hopefully the first of many similar decisions to be made by the TGA in the near future!
Things are starting to happen. TFFT.
"AusCann is developing CBD-only products at multiple dose levels using the Company’s Neuvis delivery platform. These products now have the potential to be developed and registered as pharmacy-only medicines in accordance with this TGA decision. Mr Nick Woolf, AusCann’s CEO, commented: “We are pleased that Australian policy is being driven by rigorous scientific review and is responsive to clinical evidence. The TGA decision is a positive outcome for the industry. We are well advanced in developing compliant CBD-only products that could be registered as over-the-counter medicines. These products are presented in a hard-shell capsule and offer enhanced drug absorption. This aligns with our R&D strategy to develop meaningful pharmaceuticals to address unmet medical needs.”
